Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2023）
摘要
ClinicalTrials.gov, NCT04179669.
更多查看译文
关键词
HeFH,LDL-C,PCSK9,Tafolecimab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要